‘CSL says it is paying $US200 million ($A312m) up-front to license next-generation mRNA vaccine technology from a small US company.
CSL said on Wednesday its CSL Seqirus subsidiary, the second-biggest flu vaccine manufacturer globally, has licensed the technology from NASDAQ-listed Arcturus Therapeutics.
The $US485m NASDAQ-listed company would be eligible to receive more than $US4.3 billion ($A6.7 billion) in milestone payments, plus double-digit royalties under the terms of the deal.’
au.finance.yahoo.com/news/csl-paying-312m-license-mrna-004120691.html
Views: